Novo Nordisk A/s

This study tested a new investigational medicine called CagriSema (a combination of two drugs) against tirzepatide, another weight-loss injection, in 809 adults with obesity. Participants received weekly injections under the skin for about one and a half years. The goal was to se…

This study tested a new medicine, somapacitan, given once a week against the standard daily growth hormone shot (Norditropin) in 110 Chinese children with growth hormone deficiency. The goal was to see if the weekly shot works as well for helping kids grow. Children were randomly…

This study tested a new medicine (NNC-0156-0000-0009) in 25 children with hemophilia B, a bleeding disorder. The goal was to see if the drug is safe and helps prevent or control bleeding episodes. Children received the drug regularly, and researchers tracked how many bleeds occur…

This study tested a drug called ziltivekimab in 36 adults with advanced chronic kidney disease to see if it could reduce inflammation, which is linked to heart problems. Participants received either a low dose, a high dose, or a placebo injection every 4 weeks for 3 doses. The ma…

This study tested a new weekly injection called CagriSema (a mix of two medicines) to help people with overweight or obesity and type 2 diabetes lose weight. About 1,200 adults took part, receiving either CagriSema or a placebo for around 1.5 years. The main goals were to see how…

This study tested a weekly injection of semaglutide (2.4 mg) in 207 adults with obesity and prediabetes. Participants received either the drug or a placebo for 12 months, plus lifestyle advice. The goal was to see if the drug could help them lose weight and return to normal blood…

This study looked at how well the diabetes pill Rybelsus (oral semaglutide) works in real life for adults with type 2 diabetes in the UK. Over 300 participants took the medication as prescribed by their doctor and completed questionnaires about their treatment. The main goal was …

This study tested a weekly injection of semaglutide (2.4 mg) in 201 teenagers ages 12 to 17 with overweight or obesity. Participants received either the drug or a placebo for about 15 months, along with lifestyle counseling. The main goal was to see how much their body mass index…

This study tested a new medicine called CagriSema, which combines two drugs (cagrilintide and semaglutide), to help people with excess weight lose weight. About 300 adults with a BMI of 30 or higher (or 27 with related health issues) received either CagriSema or a dummy shot once…

This early-phase study tested a new medicine, NNC0519-0130, in 161 people to see if it is safe and how it works in the body. The medicine aims to lower blood sugar and reduce appetite, which could help people with type 2 diabetes and overweight. Participants received either the m…

This study looked at how safe it is for people with hemophilia A to switch from their current medicine (emicizumab) to a new one called Mim8. Mim8 is injected under the skin weekly, every two weeks, or monthly to help prevent bleeding episodes. The study involved 61 adults and te…

This early-stage study tested a new medicine, NNC0519-0130, given as a weekly shot. The goal was to check its safety and how it affects body weight and blood sugar in 82 adults with obesity or type 2 diabetes. Participants received either the drug or a placebo for up to 37 weeks.…

This study tested a new fast-acting insulin (faster aspart) against a standard insulin (NovoRapid) in 331 adults with type 1 or type 2 diabetes. Both groups also took long-acting insulin (degludec) and could use metformin. The goal was to see if the new insulin works better at co…

This study tested whether semaglutide, a medicine used for diabetes and weight loss, can reduce inflammation in the brain and body of people with early Alzheimer's disease. Twenty-three participants received either semaglutide or a placebo for 12 weeks, then everyone received sem…

This study looked at how well Xultophy® (a combination insulin and GLP-1 medicine) controls blood sugar in adults with type 2 diabetes in Japan. Researchers followed 244 people for about 26 weeks as they used the drug as part of their normal care. The goal was to see changes in b…

This study tested a once-weekly insulin shot (icodec) combined with a flash glucose monitor (a small sensor worn on the arm) in 51 adults with type 2 diabetes who had never used insulin before. The goal was to see if this approach helps control blood sugar over 26 weeks. Particip…

This study checked the long-term safety of Ozempic in over 3,200 Japanese adults with type 2 diabetes. Participants took the drug as prescribed by their doctor for about 3 years. Researchers tracked side effects, blood sugar control, weight changes, and quality of life. The goal …

This study looked at how quickly a fast-acting insulin (faster aspart) enters the blood in 23 Chinese adults with type 1 or type 2 diabetes. Participants received one injection of the test insulin and one of the standard insulin NovoRapid, in random order. Blood samples were take…

This study followed 291 adults with type 2 diabetes whose blood sugar was not well controlled on their current medication (DPP4i). Participants switched to an oral version of semaglutide, a drug that helps lower blood sugar and may aid weight loss. Over about 5-6 months, research…

This study tested a new diabetes pill (semaglutide) against a dummy pill in 132 children and teens with type 2 diabetes. Participants took one tablet each morning on an empty stomach and waited 30 minutes before eating. The study lasted about 15 months and checked how well the me…

This study tested several medications, including semaglutide and cagrilintide, alone or together, to see if they could reduce liver damage and alcohol use in people with alcohol-related liver disease. About 270 adults with a history of heavy drinking took part. The goal was to me…

This study tested a new investigational medicine called CagriSema (a combination of two drugs) in 274 adults with type 2 diabetes who were already taking daily insulin. Participants received either CagriSema or a placebo shot once a week for about a year. The goal was to see if C…

This study tested a once-weekly injection of semaglutide (2.4 mg) in 150 Asian adults with obesity (BMI 25 or higher). Participants received either the drug or a placebo, plus lifestyle advice, for about a year. The main goal was to see how much weight they lost. Results showed t…

This study tested a new medicine, NNC0519-0130, in 299 adults with type 2 diabetes. Participants received weekly injections of different doses to see how well it lowers blood sugar and body weight. The study lasted about 40 weeks and is now complete.

This study tested whether a new investigational medicine called CagriSema (a combination of two drugs) can reduce kidney damage in people with chronic kidney disease, type 2 diabetes, and overweight or obesity. About 626 participants received either CagriSema, one of its componen…

This study tested a new weekly medicine called CagriSema, which combines two drugs (semaglutide and cagrilintide), in over 2,700 adults with type 2 diabetes. The goal was to see if the combo lowers blood sugar and body weight better than either drug alone or a placebo. Participan…

This study tested a new fast-acting insulin (NNC0471-0119) in 43 adults with type 1 diabetes who use an insulin pump. Researchers measured how quickly the insulin entered the bloodstream and lowered blood sugar, comparing it to standard insulin aspart. The goal was to see if the …

This study looked at two weight-loss medicines, cagrilintide and semaglutide, given either together in one injection or as two separate shots. The goal was to see how the different methods affect medicine levels in the blood. Forty adults with overweight or obesity received weekl…

This study used online questionnaires to learn how much healthcare providers and people with or at risk for MASH know about the disease and its links to heart, kidney, and metabolic conditions. Over 1,300 participants completed the survey, which took about 25 minutes. No treatmen…

This study follows up with people who were in the SELECT obesity medication trial to see how their health changes over the long term. No new treatment is given—participants just fill out health questionnaires every 6 months for up to 10 years. The goal is to track serious health …

This study looked at health data from over 550,000 Chinese adults to see how being overweight or obese affects heart disease. Researchers used national survey information to find out how common heart problems are in this group and how they change over time. No treatments were giv…

This study tested whether health data can be collected remotely from people with overweight or obesity using a smartphone app and connected devices like a watch and scale. 146 adults took part for 24 weeks, and no study medicine was given. The goal was to see how well remote data…

This study looked at how different levels of kidney function affect a new medicine called NNC0519-0130 for type 2 diabetes. Thirty-six adults with normal, mildly, moderately, or severely reduced kidney function received a single dose. Researchers measured the drug levels in their…

This study looked at how different amounts of water and delays before breakfast affect levels of a new semaglutide tablet in the blood. 121 healthy men took the tablet daily for 10 days. The goal was to find the best way to take the medicine for future use.

This study looked at how a high-fat meal changes the amount of the experimental drug etavopivat in the blood of 16 healthy adults. Each person took a single dose of the drug after eating a fatty meal and on an empty stomach on different days. The goal was to see if food affects h…

This early-stage study tested a single dose of a new oral medicine called etavopivat in 24 healthy Chinese volunteers. The main goal was to see how the drug moves through and is processed by the body (pharmacokinetics) and to check its initial safety and tolerability. The results…